Open-label study to assess the pharmacokinetics, safety and tolerability of siponimod in healthy subjects with CYP2C9 extensive (EM) and poor metabolizer (PM) phenotype.

Trial Profile

Open-label study to assess the pharmacokinetics, safety and tolerability of siponimod in healthy subjects with CYP2C9 extensive (EM) and poor metabolizer (PM) phenotype.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Status changed from not yet recruiting to completed, as per results presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 19 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top